Granted Patent
B2
US 12,416,636 · App. 17/059,727 · Granted Sep 16, 2025
Personalized treatment of pancreatic cancer
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed herein is a soluble protein signature from the tumor microenvironment that can predict overall survival post-surgery in pancreatic adenocarcinoma. The disclosed protein signatures provide a precision approach to surgical therapy for patients with pancreatic cancer. Also disclosed herein is a soluble protein signature from the tumor microenvironment that can diagnose pancreatic ductal adenocarcinoma (PDAC). Also disclosed herein are proteins that can be used to accurately normalize protein levels in a pancreatic sample.
Claims (13)
1. A method for treating a subject for pancreatic ductal adenocarcinoma (PDAC), consisting of
(a) assaying a tumor microenvironment sample from the subject for levels of soluble immune proteins consisting of Eotaxin, FGF-2, G-CSF, IL-4, IP-10, PDGF-AA, and TNFα;
(b) calculating a survival score based on differential expression of the soluble immune proteins; and
(c) wherein when the survival score is indicative of prolonged post-surgical survival, further comprising surgically resecting the PDAC from the subject;
wherein the tumor microenvironment sample is a fine needle aspiration (FNA) biopsy of the PDAC,
wherein levels of Eotaxin, FGF-2, IL-4, IP-10, and TNFα relative to control values are positively correlated to the survival score and levels of G-CSF and PDGF-AA relative to control values are negatively correlated to the survival score;
wherein the method is carried out in order as recited; and
wherein following step (b), the method optionally includes normalizing an amount of detected soluble immune proteins to an amount of PDGF-BB or IL-15.
2. The method of claim 1 , wherein the survival score is calculated using multivariate analysis.
3. The method of claim 1 , wherein the subject received treatment with chemotherapy, hormone therapy, radiation therapy, or a combination thereof prior to step (a).
4. The method of claim 1 , wherein the subject received treatment with portal vein resection prior to step (a).
5. The method of claim 1 , wherein the subject does not have elevated serum CA19-9 levels.
6. The method of claim 1 , wherein the subject has elevated serum CA19-9 levels.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 20, 2021
From: HUGHES, STEVEN J.
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
Reel/Frame 057531/0469 →
CONFIRMATORY LICENSE
Recorded Dec 15, 2020
From: UNIVERSITY OF FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 054760/0152 →
Continuity (2)
Provisional Application
62678572
· May 31, 2018
References Cited (50)
US 20120040861A1
· Williams et al.
· 2012
[cited by applicant]
US 20140100188A1
· Coussens
· 2014
[cited by examiner]
WO 2015164772A1
· 2015
[cited by applicant]
Yu, 2010, Clin. Chem, pp. 376-387.
[cited by examiner]
Human Cytokine/Chemokin Magnetic Bead Panel, 2013, pp. 1-32.
[cited by examiner]
Petrushnko, 2016, HPB, vol. 18: 652-663.
[cited by examiner]
Grizzle, 2010, Cancer Res. vol. 70: 2732.
[cited by examiner]
Chen, 2013, Pancreatlogy, vol. 13: 298-304.
[cited by examiner]
Chang, 2009, Gast. Endos. vol. 69: S157-S158.
[cited by examiner]
International Search Report issued for PCT/US2019/034889, mailed Aug. 15, 2019.
[cited by applicant]
Delitto et al., The Inflammatory Milieu Within the Pancreatic Cancer Microenvironment Correlates with Clinicopathologic Parameters, Chemoresistance and Survival, BMC Cancer, vol. 15, No. 783, p. 1-10, 2015.
[cited by applicant]
Brand et al., A MicroRNA-Based Test Improves Endoscopic Ultrasound-Guided Cytologic Diagnosis of Pancreatic Cancer, Clinical Gastroenterology and Hepatology, vol. 12, No. 10, p. 1717-1723, 2014.
[cited by applicant]
Liou et al., The Presence of Interleukin-13 at Pancreatic ADM/Panln Lesions Alters Macrophage Populations and Mediates Pancreatic Tumorigenesis, Cell Reports, vol. 19, No. 7, p. 1322-1333, 2017.
[cited by applicant]
Van Audenaerde et al., Interleukin-15 Stimulates Natural Killer Cell-Mediated Killing of Both Human Pancreatic Cancer and Stellate Cells, vol. 8, No. 34, p. 56968-56979, 2017.
[cited by applicant]
Turner et al., Diagnosis of pancreatic neoplasia with EUS and FNA: a report of accuracy. Gastrointest Endosc; 71(1):91-8, 2010.
[cited by applicant]
Chen et al., Diagnostic accuracy of endoscopic ultrasound-guided fineneedle aspiration for pancreatic cancer: a meta-analysis, Pancreatology;13(3):298-304, 2013.
[cited by applicant]
Eloubeidi et al., Endoscopic ultrasound-guided fine needle aspiration biopsy of patients with suspected pancreatic cancer: diagnostic accuracy and acute and 30-day complications. Am J Gastroenterol.; 98(12):2663-8, 2003.
[cited by applicant]
Shin et al., Endoscopic ultrasound-guided fine-needle aspiration in 179 cases: the M. D. Anderson Cancer Center experience. Cancer, 96(3):174-80, 2002.
[cited by applicant]
Youngwirth et al., Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients. J Surg Oncol., 116(2):127-32, 2017.
[cited by applicant]
Yamabe et al., Efforts to improve the diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration for pancreatic tumors. Endosc Ultrasound, 5(4):225-32, 2016.
[cited by applicant]
Storm et al., Endoscopic ultrasound-guided techniques for diagnosing pancreatic mass lesions: Can we do better? World J Gastroenterol., 22(39):8658-69, 20016.
[cited by applicant]
Cazacu et al., A quarter century of EUS-FNA: Progress, milestones, and future directions. Endosc Ultrasound, 7(3):141-60, 2018.
[cited by applicant]
Collins et al., Rapid on-site evaluation for endoscopic ultrasound-guided fine-needle biopsy of the pancreas decreases the incidence of repeat biopsy procedures. Cancer Cytopathol, 121(9):518-24, 2013.
[cited by applicant]
Schmidt et al., Rapid on-site evaluation increases endoscopic ultrasound-guided fine-needle aspiration adequacy for pancreatic lesions. Dig Dis Sci., 58(3):872-82, 2013.
[cited by applicant]
Kongkam et al., Combination of EUS-FNA and elastography (strain ratio) to exclude malignant solid pancreatic lesions: A prospective singleblinded study. J Gastroenterol Hepatol., 30(11):1683-9, 2015.
[cited by applicant]
Reicher et al., Fluorescence in situ hybridization and K-ras analyses improve diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses. Pancreas., 40(7):1057-62, 2011.
[cited by applicant]
Rodriguez et al., RNA sequencing distinguishes benign from malignant pancreatic lesions sampled by EUS-guided FNA. Gastrointest Endosc., 84(2):252-8, 2016.
[cited by applicant]
Szafranska et al., Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem., 54(10):1716-24, 2008.
[cited by applicant]
Chu et al., Stromal biology of pancreatic cancer. J Cell Biochem., 101(4):887-907, 2007.
[cited by applicant]
Campbell-Thompson et al., Network for Pancreatic Organ Donors with Diabetes (nPOD): developing a tissue biobank for type 1 diabetes. Diabetes Metab Res Rev., 28(7):608-17, 2012.
[cited by applicant]
Liu et al., Type 1 diabetes cadaveric human pancreata exhibit a unique exocrine tissue proteomic profile. Proteomics., 16(9):1432-46, 2016.
[cited by applicant]
R Core Team (2018). R: A language and environment for statistical computing. R Foundation for Statistical Computing V, Austria. URL https://www.R-project.org/).
[cited by applicant]
Jelle J. Goeman (2018). Penalized R package, version 0.9-51. URL https://CRAN.Rproject. org/package=penalized.
[cited by applicant]
Burnett et al., Sensitivity of alternative testing for pancreaticobiliary cancer: a 10-y review of the literature. J Surg Res., 190(2):535-47, 2014.
[cited by applicant]
Senoo et al., Immunohistochemical analysis of IMP3 and p53 expression in endoscopic ultrasound-guided fine needle aspiration and resected specimens of pancreatic diseases. Pancreatology., 8(2):176-83, 2018.
[cited by applicant]
Mei et al., EUS elastography for diagnosis of solid pancreatic masses: a meta-analysis. Gastrointest Endosc., 77(4):578-89, 2013.
[cited by applicant]
Brand et al., A microRNA-based test improves endoscopic ultrasound-guided cytologic diagnosis of pancreatic cancer. Clin Gastroenterol Hepatol., 12(10):1717-23, 2014.
[cited by applicant]
Frampton et al., Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies. Oncotarget., 10;7(19):28556-69, 2016.
[cited by applicant]
Yoon et al., Inadequate cytology in thyroid nodules: should we repeat aspiration or follow-up? Ann Surg Oncol., 18(5):1282-9, 2011.
[cited by applicant]
Bartolazzi et al., Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet., 26;357(9269):1644-50, 2001.
[cited by applicant]
Cantara et al., Molecular Signature of Indeterminate Thyroid Lesions: Current Methods to Improve Fine Needle Aspiration Cytology (FNAC) Diagnosis. Int J Mol Sci., 18(4), 2017.
[cited by applicant]
Jin et al., A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer. Int J Gynecol Cancer., 28(1):51-8, 2018.
[cited by applicant]
Muinao et al., Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells—An updated review. Exp Cell Res., 362(1):1-10, 2018.
[cited by applicant]
Trachana et al., The Development of an Angiogenic Protein “Signature” in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling. PLoS One., 11(6):e0156403, 2016.
[cited by applicant]
Gocheva et al., Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival. Proc Natl Acad Sci U S A., 114(28):E5625-E34, 2017.
[cited by applicant]
Lee et al., Development and Validation of a Novel Plasma Protein Signature for Breast Cancer Diagnosis by Using Multiple Reaction Monitoring-based Mass Spectrometry. Anticancer Res., 35(11):6271-9, 2015.
[cited by applicant]
Skoog et al., Tumor tissue protein signatures reflect histological grade of breast cancer. PLoS One., 12(6):e0179775, 2017.
[cited by applicant]
Poch et al., Systemic immune dysfunction in pancreatic cancer patients. Langenbecks Arch Surg., 392(3):353-8, 2007.
[cited by applicant]
Wang et al., From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis. Int J Mol Sci., 19(11), 2018.
[cited by applicant]
Zhuang et al., IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-kappaB Activation. Clin Cancer Res., 22(6):1432-44, 2016.
[cited by applicant]